Recommends combination of calcitonin and an intravenous bisphosphonate or denosumab as initial treatment for severe hypercalcemia (serum calcium >14 mg/dL). Indicated when a clinician notes severe HCM or seeks rapid calcium lowering in symptomatic patients.
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill es-hcm-severe-add-calcitonin-bp-dmab --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Es Hcm Severe Add Calcitonin Bp Dmab?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-es-hcm-severe-add-calcitonin-bp-dmab)More formats (shields.io, HTML) on the badges page.
---
name: es-hcm-severe-add-calcitonin-bp-dmab
description: Recommends combination of calcitonin and an intravenous bisphosphonate or denosumab as initial treatment for severe hypercalcemia (serum calcium >14 mg/dL). Indicated when a clinician notes severe HCM or seeks rapid calcium lowering in symptomatic patients.
---
# Add calcitonin to IV bisphosphonate or denosumab for severe HCM
## STEP 1 — Gather Information
Obtain serum calcium (adjusted for albumin), assess symptoms (e.g., polyuria, weakness, confusion), evaluate renal function (eGFR), and check for contraindications to calcitonin (e.g., prior tachyphylaxis). If SCa >14 mg/dL, proceed to Step 2; otherwise, consider alternative diagnoses and manage per mild/moderate HCM guidelines.
## STEP 2 — Rule In / Rule Out
Is serum calcium >14 mg/dL? If yes, rule in severe HCM and proceed to Step 3; if no, rule out severe HCM and consider other etiologies or lower-severity HCM pathways.
## STEP 3 — Classify or Stratify
Stratify by renal function: if eGFR ≥30 mL/min/1.73m², prefer intravenous bisphosphonate; if eGFR <30 mL/min/1.73m², prefer denosumab with dose adjustment. Proceed to Step 4 with selected agent.
## STEP 4 — Decide
Administer calcitonin (salmon calcitonin 4–8 units/kg IM or SC every 6–12 hours) plus the chosen antiresorptive: intravenous bisphosphonate (pamidronate 60–90 mg over 2–24 hours or zoledronic acid 4 mg over 15 minutes) or denosumab 120 mg subcutaneous. Recheck calcium in 12–24 hours.
## Clinical Guardrails / Mimics / Pitfalls
Limit calcitonin to 48–72 hours due to tachyphylaxis; monitor serum calcium and phosphorus every 12–24 hours to avoid hypocalcemia; ensure adequate hydration before bisphosphonate; adjust bisphosphonate dose for renal impairment (e.g., pamidronate over 2–24 hours if eGFR <30); denosumab requires vitamin D repletion and calcium supplementation in deficient patients; do not use calcitonin monotherapy; avoid in patients with known salmon polypeptide allergy.
## Concrete Clinical Example
A 68-year-old with metastatic lung cancer presents with SCa 15.2 mg/dL, polyuria, and nausea. eGFR is 45 mL/min/1.73m². Give calcitonin 4 units/kg SC every 6 hours plus zoledronic acid 4 mg IV over 15 minutes. After 24 hours, SCa drops to 12.8 mg/dL; continue denosumab 120 mg SC weekly for 3 doses then monthly, discontinuing calcitonin after 60 hours.
**Source:** Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac621
> **TODO:** consider adding scripts/calc.py for the es-hcm-severe-add-calcitonin-bp-dmab calculator
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!